United States Biotechnology & Medical Research

Pyxis Oncology Inc (PYXS)

Track

Track

Pyxis Oncology Inc. recorded two recent insider trading transactions involving director Jakob Dupont, who executed planned sales totaling approximately $214,134. These divestments occurred following a 49% stock price increase over the last quarter. No other significant activity was reported since the company's latest results financiers.
Ticker: PYXS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Pyxis Oncology Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Dupont Jakob Non-Executive Director
Transaction date
Planned sale
Price
197.07
Quantity 97,337 +27.4%
Value US$3,972,402
Dupont Jakob Director Non-Executive Director
Transaction date
Proposed sale
Price
106.23
Quantity 50,350
Value US$2,628,056
HUMPHREY RACHEL Non-Executive Director
Transaction date
Planned sale
Price
95.46
Quantity 25,142 +18.5%
Value US$3,722,616
HUMPHREY RACHEL Director Non-Executive Director
Transaction date
Proposed sale
Price
1.03
Quantity 13,896
Value US$14,362
HUMPHREY RACHEL Non-Executive Director
Transaction date
Planned sale
Price
0.97
Quantity 200 -0.2%
Value US$194
HUMPHREY RACHEL Director Non-Executive Director
Transaction date
Proposed sale
Price
0.97
Quantity 200
Value US$194
HUMPHREY RACHEL Non-Executive Director
Transaction date
Planned sale
Price
0.97
Quantity 1,400 -1.4%
Value US$1,362
HUMPHREY RACHEL Director Non-Executive Director
Transaction date
Proposed sale
Price
0.97
Quantity 1,400
Value US$1,362
1.5
Connealy Pamela Ann CFO & COO Officer
Transaction date
Purchase
Price
1.96
Quantity 83,400 +7.5%
Value US$163,464
1.5
Connealy Pamela Ann CFO & COO Officer
Transaction date
Purchase
Price
2.00
Quantity 5,450 +0.5%
Value US$10,900
1.5
Connealy Pamela Ann CFO and COO Officer
Transaction date
Purchase
Price
1.87
Quantity 8,000 +1.0%
Value US$14,960
1.5
Connealy Pamela Ann CFO and COO Officer
Transaction date
Purchase
Price
1.85
Quantity 6,426 +0.8%
Value US$11,868
2.0
Wadhane Jitendra Chief Accounting Officer Officer
Transaction date
Purchase
Price
1.87
Quantity 2,500 +1.1%
Value US$4,675
2.0
Wadhane Jitendra Chief Accounting Officer Officer
Transaction date
Purchase
Price
1.77
Quantity 5,000 +2.3%
Value US$8,850
1.5
Connealy Pamela Ann CFO and COO Officer
Transaction date
Purchase
Price
1.67
Quantity 12,000 +1.5%
Value US$20,044
1.5
Connealy Pamela Ann CFO and COO Officer
Transaction date
Purchase
Price
1.74
Quantity 5,000 +0.6%
Value US$8,695
2.0
Wadhane Jitendra Chief Accounting Officer Officer
Transaction date
Purchase
Price
1.74
Quantity 2,500 +1.2%
Value US$4,349
3.1
Sullivan Lara Officer; Director Executive Director
Transaction date
Proposed sale
Price
2.10
Quantity 8,541
Value US$17,936
3.1
Sullivan Lara President and CEO Executive Director
Transaction date
Sale
Price
2.10
Quantity 8,541 -0.4%
Value US$17,936
3.1
Sullivan Lara President and CEO Executive Director
Transaction date
Sale
Price
2.25
Quantity 100 -0.0%
Value US$225
3.1
Sullivan Lara Officer; Director Executive Director
Transaction date
Proposed sale
Price
2.25
Quantity 100
Value US$225
3.1
Sullivan Lara Officer; Director Executive Director
Transaction date
Proposed sale
Price
2.27
Quantity 3,000
Value US$6,816
3.1
Sullivan Lara President and CEO Executive Director
Transaction date
Sale
Price
2.27
Quantity 3,000 -0.1%
Value US$6,816
3.1
Sullivan Lara President and CEO Executive Director
Transaction date
Sale
Price
2.25
Quantity 4,917 -0.2%
Value US$11,071
3.1
Sullivan Lara Officer; Director Executive Director
Transaction date
Proposed sale
Price
2.25
Quantity 4,917
Value US$11,071
3.1
Sullivan Lara President and CEO Executive Director
Transaction date
Sale
Price
2.27
Quantity 20,000 -0.8%
Value US$45,414
3.1
Sullivan Lara Officer; Director Executive Director
Transaction date
Proposed sale
Price
2.27
Quantity 20,000
Value US$45,414
Feingold Jay Former Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.37
Quantity 18,109
Value US$42,919
Feingold Jay Former Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.53
Quantity 50,000
Value US$126,481
Feingold Jay Former Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.52
Quantity 25,000
Value US$63,070
Feingold Jay Former Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.58
Quantity 25,000
Value US$64,605
Feingold Jay Former Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.43
Quantity 23,021
Value US$56,009
Feingold Jay Former Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.43
Quantity 23,021
Value US$56,009
Feingold Jay Former Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.61
Quantity 27,361
Value US$71,380
Feingold Jay Former Officer Officer
Transaction date
Proposed sale
Price
2.77
Quantity 30,000
Value US$83,059
Feingold Jay Officer Officer
Transaction date
Proposed sale
Price
2.97
Quantity 234
Value US$695
Feingold Jay Officer Officer
Transaction date
Proposed sale
Price
3.01
Quantity 23,637
Value US$71,107
Feingold Jay Officer Officer
Transaction date
Proposed sale
Price
3.12
Quantity 37,402
Value US$116,728
3.4
PFIZER INC Large shareholder
Transaction date
Purchase
Price
2.76
Quantity 1,811,594 +43.8%
Value US$4,999,999
2.8
Chin Mark Former Director
Transaction date
Sale
Price
3.05
Quantity 1,745,761 -100.0%
Value US$5,324,571
1.3
Cline Darren S Non-Executive Director
Transaction date
Purchase
Price
9.39
Quantity 10,000 +inf%
Value US$93,885
0.8
Civik Thomas Non-Executive Director
Transaction date
Purchase
Price
12.74
Quantity 15,700 +inf%
Value US$200,018
2.8
Chin Mark Non-Executive Director
Transaction date
Purchase
Price
16.00
Quantity 312,500 +21.8%
Value US$5,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-02 2026-06-30 PlS Planned sale
Dupont Jakob
Non-Executive Director
97,337 +27.4%
197.07
US$3,972,402 		97,337 +27.4% 197.07 US$3,972,402
2026-06-30 2026-06-30 PrS Proposed sale
Dupont Jakob

Director

Non-Executive Director
50,350
106.23
US$2,628,056 		50,350 106.23 US$2,628,056
2026-03-25 2025-04-21 PlS Planned sale
HUMPHREY RACHEL
Non-Executive Director
25,142 +18.5%
95.46
US$3,722,616 		25,142 +18.5% 95.46 US$3,722,616
2025-04-21 2025-04-21 PrS Proposed sale
HUMPHREY RACHEL

Director

Non-Executive Director
13,896
1.03
US$14,362 		13,896 1.03 US$14,362
2026-03-25 2025-04-17 PlS Planned sale
HUMPHREY RACHEL
Non-Executive Director
200 -0.2%
0.97
US$194 		200 -0.2% 0.97 US$194
2025-04-17 2025-04-17 PrS Proposed sale
HUMPHREY RACHEL

Director

Non-Executive Director
200
0.97
US$194 		200 0.97 US$194
2026-03-25 2025-04-14 PlS Planned sale
HUMPHREY RACHEL
Non-Executive Director
1,400 -1.4%
0.97
US$1,362 		1,400 -1.4% 0.97 US$1,362
2025-04-14 2025-04-14 PrS Proposed sale
HUMPHREY RACHEL

Director

Non-Executive Director
1,400
0.97
US$1,362 		1,400 0.97 US$1,362
2024-11-27 2024-11-26 B Purchase
1.5
Connealy Pamela Ann

CFO & COO

Officer
83,400 +7.5%
1.96
US$163,464 		83,400 +7.5% 1.96 US$163,464
2024-11-27 2024-11-26 B Purchase
1.5
Connealy Pamela Ann

CFO & COO

Officer
5,450 +0.5%
2.00
US$10,900 		5,450 +0.5% 2.00 US$10,900
2023-09-28 2023-09-28 B Purchase
1.5
Connealy Pamela Ann

CFO and COO

Officer
8,000 +1.0%
1.87
US$14,960 		8,000 +1.0% 1.87 US$14,960
2023-09-27 2023-09-27 B Purchase
1.5
Connealy Pamela Ann

CFO and COO

Officer
6,426 +0.8%
1.85
US$11,868 		6,426 +0.8% 1.85 US$11,868
2023-09-27 2023-09-27 B Purchase
2.0
Wadhane Jitendra

Chief Accounting Officer

Officer
2,500 +1.1%
1.87
US$4,675 		2,500 +1.1% 1.87 US$4,675
2023-09-25 2023-09-25 B Purchase
2.0
Wadhane Jitendra

Chief Accounting Officer

Officer
5,000 +2.3%
1.77
US$8,850 		5,000 +2.3% 1.77 US$8,850
2023-09-25 2023-09-25 B Purchase
1.5
Connealy Pamela Ann

CFO and COO

Officer
12,000 +1.5%
1.67
US$20,044 		12,000 +1.5% 1.67 US$20,044
2023-09-22 2023-09-22 B Purchase
1.5
Connealy Pamela Ann

CFO and COO

Officer
5,000 +0.6%
1.74
US$8,695 		5,000 +0.6% 1.74 US$8,695
2023-09-22 2023-09-22 B Purchase
2.0
Wadhane Jitendra

Chief Accounting Officer

Officer
2,500 +1.2%
1.74
US$4,349 		2,500 +1.2% 1.74 US$4,349
2023-09-18 2023-09-18 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
8,541
2.10
US$17,936 		8,541 2.10 US$17,936
2023-09-18 2023-09-18 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
8,541 -0.4%
2.10
US$17,936 		8,541 -0.4% 2.10 US$17,936
2023-09-18 2023-09-14 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
100 -0.0%
2.25
US$225 		100 -0.0% 2.25 US$225
2023-09-14 2023-09-14 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
100
2.25
US$225 		100 2.25 US$225
2023-09-13 2023-09-13 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
3,000
2.27
US$6,816 		3,000 2.27 US$6,816
2023-09-13 2023-09-13 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
3,000 -0.1%
2.27
US$6,816 		3,000 -0.1% 2.27 US$6,816
2023-09-13 2023-09-12 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
4,917 -0.2%
2.25
US$11,071 		4,917 -0.2% 2.25 US$11,071
2023-09-12 2023-09-12 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
4,917
2.25
US$11,071 		4,917 2.25 US$11,071
2023-09-13 2023-09-11 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
20,000 -0.8%
2.27
US$45,414 		20,000 -0.8% 2.27 US$45,414
2023-09-11 2023-09-11 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
20,000
2.27
US$45,414 		20,000 2.27 US$45,414
2023-09-05 2023-09-05 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
18,109
2.37
US$42,919 		18,109 2.37 US$42,919
2023-08-11 2023-08-11 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
50,000
2.53
US$126,481 		50,000 2.53 US$126,481
2023-08-01 2023-08-01 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
25,000
2.52
US$63,070 		25,000 2.52 US$63,070
2023-07-31 2023-07-31 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
25,000
2.58
US$64,605 		25,000 2.58 US$64,605
2023-07-28 2023-07-27 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
23,021
2.43
US$56,009 		23,021 2.43 US$56,009
2023-07-27 2023-07-27 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
23,021
2.43
US$56,009 		23,021 2.43 US$56,009
2023-07-21 2023-07-21 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
27,361
2.61
US$71,380 		27,361 2.61 US$71,380
2023-07-11 2023-07-11 PrS Proposed sale
Feingold Jay

Former Officer

Officer
30,000
2.77
US$83,059 		30,000 2.77 US$83,059
2023-06-16 2023-06-16 PrS Proposed sale
Feingold Jay

Officer

Officer
234
2.97
US$695 		234 2.97 US$695
2023-06-08 2023-06-08 PrS Proposed sale
Feingold Jay

Officer

Officer
23,637
3.01
US$71,107 		23,637 3.01 US$71,107
2023-06-07 2023-06-07 PrS Proposed sale
Feingold Jay

Officer

Officer
37,402
3.12
US$116,728 		37,402 3.12 US$116,728
2023-03-21 2023-03-17 B Purchase
3.4
PFIZER INC
Large shareholder
1,811,594 +43.8%
2.76
US$4,999,999 		1,811,594 +43.8% 2.76 US$4,999,999
2022-04-25 2022-04-21 S Sale
2.8
Chin Mark

Former Director
1,745,761 -100.0%
3.05
US$5,324,571 		1,745,761 -100.0% 3.05 US$5,324,571
2021-12-09 2021-12-08 B Purchase
1.3
Cline Darren S
Non-Executive Director
10,000 +inf%
9.39
US$93,885 		10,000 +inf% 9.39 US$93,885
2021-11-19 2021-11-18 B Purchase
0.8
Civik Thomas
Non-Executive Director
15,700 +inf%
12.74
US$200,018 		15,700 +inf% 12.74 US$200,018
2021-10-15 2021-10-13 B Purchase
2.8
Chin Mark
Non-Executive Director
312,500 +21.8%
16.00
US$5,000,000 		312,500 +21.8% 16.00 US$5,000,000
2021-10-15 2021-10-13 B Purchase
3.7
Cormorant Asset Management, LP
450,000 +67.3%
16.00
US$7,200,000 		450,000 +67.3% 16.00 US$7,200,000
Explore more

More insider trading research around Pyxis Oncology Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America